The SSADH Association is a voluntary, not-for-profit, 501(c) (3) organization dedicated to helping children and families affected by an ultra-rare neurometabolic disorder known as Succinic Semialdehyde Dehydrogenase Deficiency or SSADH.
The SSADH Association is committed to those affected with this neurotransmitter disease through education, advocacy and research.
News & Updates
Gamma-Hydroxybutyrate Content in Dried Bloodspots Facilitates Newborn Detection of Succinic Semialdehyde Dehydrogenase Deficiency. Further, development of a first-tier screening method…Read More
The research team of Drs. Gibson and Roullet makes the news in the WSU Insider. An article titled, Worldwide Rare Disease Study Led by WSU Researchers, by Judith Van Dongen, WSU Spokane Office of Research, talks about the grant received from the National Institute of Child Health and Human Development to conduct a natural history study for SSADH patients.
The article details the importance of the natural history study and explains how it will help the scientists identify specific biomarkers of disease severity and better predict the natural course of SSADH. Additionally, the article talks about the importance of the natural history study and explains how it will meet prerequisites for FDA approval of new drugs or existing drugs indicated for other conditions.
Mike Gibson, far left, and Jean‑Baptiste Roullet (blue sweater) and their team of researchers in the WSU College of Pharmacy and Pharmaceutical Sciences.
(Photo by Cori Kogan, WSU Spokane)
For more information or to enroll in the study please email:
Study Coordinator: Dr. Melissa DiBacco by email at: Melissa.Dibacco@childrens.harvard.edu
Study Coordinator: Dr. Kathrin Jeltsch by email at: Kathrin.Jeltsch@med.uni-heidelberg.de